<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334747</url>
  </required_header>
  <id_info>
    <org_study_id>CKAE609A2202</org_study_id>
    <secondary_id>207813/Z/17/Z</secondary_id>
    <nct_id>NCT03334747</nct_id>
  </id_info>
  <brief_title>Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.</brief_title>
  <official_title>A Phase 2, Multi-center, Randomized, Open-label, Dose-escalation Study to Determine Safety of Single (QD) and Multiple (3 QD) Doses of KAE609, Given to Adults With Uncomplicated Plasmodium Falciparum Malaria.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Supported by Wellcome Trust via Grant # Grant Number 207813/Z/17/Z</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      KAE609 will be evaluated primarily for hepatic safety of single and multiple doses in&#xD;
      sequential cohorts with increasing doses.This study aims to determine the maximum safe dose&#xD;
      of the investigational drug KAE609 in malaria patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Actual">November 23, 2019</completion_date>
  <primary_completion_date type="Actual">November 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients were randomized to KAE609 and Coartem in parallel treatment arms. Increasing doses of KAE609 (single dose and multiple dose) were evaluated in dose escalated manner in sequential cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With at Least 2 CTCAE Grades Increase From Baseline in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)</measure>
    <time_frame>Day 29</time_frame>
    <description>The occurrence of at least 2 CTCAE grades increase from baseline in ALT or AST during the 4 weeks study period was evaluated to characterize hepatic safety aspects of single and multiple ascending doses of KAE609 in adult malaria subjects for treatment of uncomplicated malaria caused by plasmodium falciparum. If 2 patients in a 10 patient cohort (Cohorts 1 and 2) or 3 patients in a 20 patient cohort (Cohorts 3, 4 and 5) had at least 2 CTCAE grades increase from Baseline in ALT or AST, recruitment was suspended and a review of liver safety (and any other relevant data) by safety review committee was initiated. Any further progression of the study was based on the decision by the safety review committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected and Uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 15 and Day 29</measure>
    <time_frame>Day 15, Day 29</time_frame>
    <description>PCR-corrected and PCR-uncorrected were evaluated at Days 15 and 29 (i.e., 14 and 28 days post-dose). The presence of parasitaemia after 7 days due to reinfection was considered as PCR-corrected ACPR. Missing blood smear data at Day 15 visit and thereafter were not considered as responder for the visit unless there was a later blood smear test indicating no parasitaemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Time (PCT)</measure>
    <time_frame>Day 29</time_frame>
    <description>Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 48 hours. In case a patient received rescue medication before (parasite) clearance, the time to event was censored at the first use of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance Time (FCT)</measure>
    <time_frame>Day 29</time_frame>
    <description>Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral/tympanic/rectal for at least a further 24 hours. In case a patient received rescue medication before (fever) clearance, the time to event was censored at the first use of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recrudescence and Reinfection at Study Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Time to recrudescence is calculated from the date of first study medication to the date of first event. Participants without recrudescence/reinfection after Day 7 are censored at the time of treatment failure or at the time of last parasite assessment if no treatment failure occured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Peak Observed Concentration (Cmax)</measure>
    <time_frame>Day 1, Day 3</time_frame>
    <description>Maximum Peak Observed Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1, Day 3</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>Day 1, Day 3</time_frame>
    <description>AUC0-24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T^1/2)</measure>
    <time_frame>Upto day 15 post dose</time_frame>
    <description>Half-life (T^1/2)</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Treatment arm 1: KAE609 10 mg Single Dose (SD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAE609 10 mg once daily (QD) for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 2:KAE609 25 mg SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAE609 25 mg once daily (QD) for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 3:KAE609 10 mg 3 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAE609 10 mg (QD) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 4:KAE609 50 mg SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAE609 50 mg once daily (QD) for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 5:KAE609 25 mg 3 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAE609 25 mg once daily (QD) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 6:KAE609 75 mg SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAE609 75 mg once daily (QD) for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 7:KAE609 50 mg 3 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAE609 50 mg once daily (QD) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 8: KAE609 150 mg SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAE609 150 mg once daily (QD) for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 9: Coartem Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coartem® control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAE609</intervention_name>
    <description>Exploration of different doses of KAE609 to establish safety profile.</description>
    <arm_group_label>Treatment arm 1: KAE609 10 mg Single Dose (SD)</arm_group_label>
    <arm_group_label>Treatment arm 2:KAE609 25 mg SD</arm_group_label>
    <arm_group_label>Treatment arm 3:KAE609 10 mg 3 Days</arm_group_label>
    <arm_group_label>Treatment arm 4:KAE609 50 mg SD</arm_group_label>
    <arm_group_label>Treatment arm 5:KAE609 25 mg 3 Days</arm_group_label>
    <arm_group_label>Treatment arm 6:KAE609 75 mg SD</arm_group_label>
    <arm_group_label>Treatment arm 7:KAE609 50 mg 3 Days</arm_group_label>
    <arm_group_label>Treatment arm 8: KAE609 150 mg SD</arm_group_label>
    <other_name>Cipargamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coartem</intervention_name>
    <description>Control Arm</description>
    <arm_group_label>Treatment arm 9: Coartem Control</arm_group_label>
    <other_name>Artemether Lumefantrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        KEY Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients ≥ 18 years with a body weight ≥ 45 kg.&#xD;
&#xD;
          2. Microscopic confirmation of acute uncomplicated P. falciparum using by Giemsa-stained&#xD;
             thick film.&#xD;
&#xD;
          3. P. falciparum parasitaemia of 500 to 50 000 parasites/µL.&#xD;
&#xD;
          4. Axillary temperature ≥ 37.5ºC or oral/tympanic/rectal temperature ≥ 38.0ºC; or history&#xD;
             of fever during the previous 24 hours.&#xD;
&#xD;
          5. Written informed consent must be obtained before any study assessment is performed. If&#xD;
             the patient is unable to write, then a witnessed consent according to local ethical&#xD;
             standards is permitted.&#xD;
&#xD;
        KEY Exclusion Criteria:&#xD;
&#xD;
          1. Mixed Plasmodium infections.&#xD;
&#xD;
          2. Signs and symptoms of severe malaria according to World Health Organization (WHO) 2016&#xD;
             criteria (WHO 2016).&#xD;
&#xD;
          3. Known liver abnormalities, liver cirrhosis (compensated or decompensated), known&#xD;
             active or history of hepatitis B or C (testing not required), known gallbladder or&#xD;
             bile duct disease, acute or chronic pancreatitis.&#xD;
&#xD;
          4. Clinical or laboratory evidence of any of the following:&#xD;
&#xD;
          5. AST/ALT &gt; 1.5 x the upper limit of normal range (ULN), regardless of the level of&#xD;
             total bilirubin&#xD;
&#xD;
          6. AST/ALT &gt; 1.0 and ≤ 1.5 x ULN and total bilirubin is &gt; ULN&#xD;
&#xD;
          7. Total bilirubin &gt; 2 x ULN, regardless of the level of AST/ALT&#xD;
&#xD;
          8. History of photodermatitis/increased sensitivity to sun.&#xD;
&#xD;
          9. Pregnant or nursing (lactating) women.&#xD;
&#xD;
         10. Known disturbances of electrolyte balance, e.g. hypokalemia, hypocalcemia or&#xD;
             hypomagnesemia.&#xD;
&#xD;
         11. Moderate to severe anemia (Hemoglobin level &lt;8 g/dL).&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lambarene</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kintampo</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Navrango</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sotuba</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bushenyi</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gabon</country>
    <country>Ghana</country>
    <country>Mali</country>
    <country>Rwanda</country>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=726</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <results_first_submitted>September 3, 2020</results_first_submitted>
  <results_first_submitted_qc>September 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2020</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uncomplicated Plasmodium falciparum Malaria.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03334747/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03334747/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in 10 centers in 5 countries: Mali (2), Uganda (3), Ghana (2), Gabon (1), Rwanda (2).</recruitment_details>
      <pre_assignment_details>Approximately, 210 patients were planned to be randomized in six cohorts (KAE609: 150 and Coartem: 60). A total of 188 (KAE609: 137 and Coartem: 51) subjects were randomized in five cohorts. Cohort 6 was optional and never initiated. Two of the 188 randomized subjects were not treated and therefore were excluded from all analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>KAE609 10 mg SD</title>
          <description>KAE609 10 mg once daily (QD) for 1 day</description>
        </group>
        <group group_id="P2">
          <title>KAE609 10 mg QD 3 Days</title>
          <description>KAE609 10 mg (QD) for 3 days</description>
        </group>
        <group group_id="P3">
          <title>KAE609 25 mg SD</title>
          <description>KAE609 25 mg once daily (QD) for 1 day</description>
        </group>
        <group group_id="P4">
          <title>KAE609 25 mg QD 3 Days</title>
          <description>KAE609 25 mg once daily (QD) for 3 days</description>
        </group>
        <group group_id="P5">
          <title>KAE609 50 mg SD</title>
          <description>KAE609 50 mg once daily (QD) for 1 day</description>
        </group>
        <group group_id="P6">
          <title>KAE609 50 mg QD 3 Days</title>
          <description>KAE609 50 mg once daily (QD) for 3 days</description>
        </group>
        <group group_id="P7">
          <title>KAE609 75 mg SD</title>
          <description>KAE609 75 mg once daily (QD) for 1 day</description>
        </group>
        <group group_id="P8">
          <title>KAE609 150 mg SD</title>
          <description>KAE609 150 mg once daily (QD) for 1 day</description>
        </group>
        <group group_id="P9">
          <title>Pooled Coartem Control</title>
          <description>control arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="21"/>
                <participants group_id="P8" count="22"/>
                <participants group_id="P9" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="21"/>
                <participants group_id="P8" count="22"/>
                <participants group_id="P9" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="21"/>
                <participants group_id="P8" count="22"/>
                <participants group_id="P9" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="22"/>
                <participants group_id="P9" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized set (RAN)</population>
      <group_list>
        <group group_id="B1">
          <title>KAE609 10 mg SD</title>
          <description>KAE609 10 mg once daily (QD) for 1 day</description>
        </group>
        <group group_id="B2">
          <title>KAE609 10 mg QD 3 Days</title>
          <description>KAE609 10 mg (QD) for 3 days</description>
        </group>
        <group group_id="B3">
          <title>KAE609 25 mg SD</title>
          <description>KAE609 25 mg once daily (QD) for 1 day</description>
        </group>
        <group group_id="B4">
          <title>KAE609 25 mg QD 3 Days</title>
          <description>KAE609 25 mg once daily (QD) for 3 days</description>
        </group>
        <group group_id="B5">
          <title>KAE609 50 mg SD</title>
          <description>KAE609 50 mg once daily (QD) for 1 day</description>
        </group>
        <group group_id="B6">
          <title>KAE609 50 mg QD 3 Days</title>
          <description>KAE609 50 mg once daily (QD) for 3 days</description>
        </group>
        <group group_id="B7">
          <title>KAE609 75 mg SD</title>
          <description>KAE609 75 mg once daily (QD) for 1 day</description>
        </group>
        <group group_id="B8">
          <title>KAE609 150 mg SD</title>
          <description>KAE609 150 mg once daily (QD) for 1 day</description>
        </group>
        <group group_id="B9">
          <title>Pooled Coartem Control</title>
          <description>control arm</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="22"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="21"/>
            <count group_id="B8" value="22"/>
            <count group_id="B9" value="51"/>
            <count group_id="B10" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="10.48"/>
                    <measurement group_id="B2" value="35.4" spread="13.25"/>
                    <measurement group_id="B3" value="33.0" spread="14.96"/>
                    <measurement group_id="B4" value="31.9" spread="10.67"/>
                    <measurement group_id="B5" value="33.9" spread="12.56"/>
                    <measurement group_id="B6" value="26.4" spread="7.18"/>
                    <measurement group_id="B7" value="28.2" spread="10.25"/>
                    <measurement group_id="B8" value="30.6" spread="12.57"/>
                    <measurement group_id="B9" value="26.2" spread="9.07"/>
                    <measurement group_id="B10" value="29.7" spread="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="33"/>
                    <measurement group_id="B10" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="51"/>
                    <measurement group_id="B10" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least 2 CTCAE Grades Increase From Baseline in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)</title>
        <description>The occurrence of at least 2 CTCAE grades increase from baseline in ALT or AST during the 4 weeks study period was evaluated to characterize hepatic safety aspects of single and multiple ascending doses of KAE609 in adult malaria subjects for treatment of uncomplicated malaria caused by plasmodium falciparum. If 2 patients in a 10 patient cohort (Cohorts 1 and 2) or 3 patients in a 20 patient cohort (Cohorts 3, 4 and 5) had at least 2 CTCAE grades increase from Baseline in ALT or AST, recruitment was suspended and a review of liver safety (and any other relevant data) by safety review committee was initiated. Any further progression of the study was based on the decision by the safety review committee.</description>
        <time_frame>Day 29</time_frame>
        <population>Safety Set (SAF). Only participants with baseline and at least one post-baseline assessment for either ALT or AST are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>KAE609 10 mg SD</title>
            <description>KAE609 10 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O2">
            <title>KAE609 10 mg QD 3 Days</title>
            <description>KAE609 10 mg (QD) for 3 days</description>
          </group>
          <group group_id="O3">
            <title>KAE609 25 mg SD</title>
            <description>KAE609 25 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O4">
            <title>KAE609 25 mg QD 3 Days</title>
            <description>KAE609 25 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O5">
            <title>KAE609 50 mg SD</title>
            <description>KAE609 50 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O6">
            <title>KAE609 50 mg QD 3 Days</title>
            <description>KAE609 50 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O7">
            <title>KAE609 75 mg SD</title>
            <description>KAE609 75 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O8">
            <title>KAE609 150 mg SD</title>
            <description>KAE609 150 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O9">
            <title>Pooled Coartem Control</title>
            <description>control arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least 2 CTCAE Grades Increase From Baseline in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)</title>
          <description>The occurrence of at least 2 CTCAE grades increase from baseline in ALT or AST during the 4 weeks study period was evaluated to characterize hepatic safety aspects of single and multiple ascending doses of KAE609 in adult malaria subjects for treatment of uncomplicated malaria caused by plasmodium falciparum. If 2 patients in a 10 patient cohort (Cohorts 1 and 2) or 3 patients in a 20 patient cohort (Cohorts 3, 4 and 5) had at least 2 CTCAE grades increase from Baseline in ALT or AST, recruitment was suspended and a review of liver safety (and any other relevant data) by safety review committee was initiated. Any further progression of the study was based on the decision by the safety review committee.</description>
          <population>Safety Set (SAF). Only participants with baseline and at least one post-baseline assessment for either ALT or AST are included in the analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="0.3" upper_limit="48.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="30.8"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="26.5"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="16.8"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="16.1"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="16.1"/>
                    <measurement group_id="O8" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O9" value="3.9" lower_limit="0.5" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.391</p_value>
            <method>Fisher Exact</method>
            <method_desc>2-sided p-value results from Fisher exact test for each KAE609 treatment group compared to Pooled Coartem</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
            <method_desc>2-sided p-value results from Fisher exact test for each KAE609 treatment group compared to Pooled Coartem</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
            <method_desc>2-sided p-value results from Fisher exact test for each KAE609 treatment group compared to Pooled Coartem</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
            <method_desc>2-sided p-value results from Fisher exact test for each KAE609 treatment group compared to Pooled Coartem</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
            <method_desc>2-sided p-value results from Fisher exact test for each KAE609 treatment group compared to Pooled Coartem</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
            <method_desc>2-sided p-value results from Fisher exact test for each KAE609 treatment group compared to Pooled Coartem</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
            <method_desc>2-sided p-value results from Fisher exact test for each KAE609 treatment group compared to Pooled Coartem</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
            <method_desc>2-sided p-value results from Fisher exact test for each KAE609 treatment group compared to Pooled Coartem</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected and Uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 15 and Day 29</title>
        <description>PCR-corrected and PCR-uncorrected were evaluated at Days 15 and 29 (i.e., 14 and 28 days post-dose). The presence of parasitaemia after 7 days due to reinfection was considered as PCR-corrected ACPR. Missing blood smear data at Day 15 visit and thereafter were not considered as responder for the visit unless there was a later blood smear test indicating no parasitaemia.</description>
        <time_frame>Day 15, Day 29</time_frame>
        <population>Full Analysis Set (FAS). Only responders at each timepoint are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>KAE609 10 mg SD</title>
            <description>KAE609 10 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O2">
            <title>KAE609 10 mg QD 3 Days</title>
            <description>KAE609 10 mg (QD) for 3 days</description>
          </group>
          <group group_id="O3">
            <title>KAE609 25 mg SD</title>
            <description>KAE609 25 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O4">
            <title>KAE609 25 mg QD 3 Days</title>
            <description>KAE609 25 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O5">
            <title>KAE609 50 mg SD</title>
            <description>KAE609 50 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O6">
            <title>KAE609 50 mg QD 3 Days</title>
            <description>KAE609 50 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O7">
            <title>KAE609 75 mg SD</title>
            <description>KAE609 75 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O8">
            <title>KAE609 150 mg SD</title>
            <description>KAE609 150 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O9">
            <title>Pooled Coartem Control</title>
            <description>control arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected and Uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 15 and Day 29</title>
          <description>PCR-corrected and PCR-uncorrected were evaluated at Days 15 and 29 (i.e., 14 and 28 days post-dose). The presence of parasitaemia after 7 days due to reinfection was considered as PCR-corrected ACPR. Missing blood smear data at Day 15 visit and thereafter were not considered as responder for the visit unless there was a later blood smear test indicating no parasitaemia.</description>
          <population>Full Analysis Set (FAS). Only responders at each timepoint are included in the analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15: PCR corrected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="55.50" upper_limit="99.75"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.50" upper_limit="99.75"/>
                    <measurement group_id="O3" value="83.3" lower_limit="51.59" upper_limit="97.91"/>
                    <measurement group_id="O4" value="95.0" lower_limit="75.13" upper_limit="99.87"/>
                    <measurement group_id="O5" value="95.2" lower_limit="76.18" upper_limit="99.88"/>
                    <measurement group_id="O6" value="84.2" lower_limit="60.42" upper_limit="96.62"/>
                    <measurement group_id="O7" value="90.5" lower_limit="69.62" upper_limit="98.83"/>
                    <measurement group_id="O8" value="77.3" lower_limit="54.63" upper_limit="92.18"/>
                    <measurement group_id="O9" value="96.1" lower_limit="86.54" upper_limit="99.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: PCR uncorrected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="55.50" upper_limit="99.75"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.50" upper_limit="99.75"/>
                    <measurement group_id="O3" value="83.3" lower_limit="51.59" upper_limit="97.91"/>
                    <measurement group_id="O4" value="95.0" lower_limit="75.13" upper_limit="99.87"/>
                    <measurement group_id="O5" value="95.2" lower_limit="76.18" upper_limit="99.88"/>
                    <measurement group_id="O6" value="84.2" lower_limit="60.42" upper_limit="96.62"/>
                    <measurement group_id="O7" value="85.7" lower_limit="63.66" upper_limit="96.95"/>
                    <measurement group_id="O8" value="77.3" lower_limit="54.63" upper_limit="92.18"/>
                    <measurement group_id="O9" value="96.1" lower_limit="86.54" upper_limit="99.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: PCR corrected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="44.39" upper_limit="97.48"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.50" upper_limit="99.75"/>
                    <measurement group_id="O3" value="83.3" lower_limit="51.59" upper_limit="97.91"/>
                    <measurement group_id="O4" value="90.0" lower_limit="68.30" upper_limit="98.77"/>
                    <measurement group_id="O5" value="85.7" lower_limit="63.66" upper_limit="96.95"/>
                    <measurement group_id="O6" value="73.7" lower_limit="48.80" upper_limit="90.85"/>
                    <measurement group_id="O7" value="81.0" lower_limit="58.09" upper_limit="94.55"/>
                    <measurement group_id="O8" value="68.2" lower_limit="45.13" upper_limit="86.14"/>
                    <measurement group_id="O9" value="94.1" lower_limit="83.76" upper_limit="98.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: PCR uncorrected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="44.39" upper_limit="97.48"/>
                    <measurement group_id="O2" value="90.0" lower_limit="55.50" upper_limit="99.75"/>
                    <measurement group_id="O3" value="66.7" lower_limit="34.89" upper_limit="90.08"/>
                    <measurement group_id="O4" value="80.0" lower_limit="56.34" upper_limit="94.27"/>
                    <measurement group_id="O5" value="81.0" lower_limit="58.09" upper_limit="94.55"/>
                    <measurement group_id="O6" value="68.4" lower_limit="43.45" upper_limit="87.42"/>
                    <measurement group_id="O7" value="71.4" lower_limit="47.82" upper_limit="88.72"/>
                    <measurement group_id="O8" value="59.1" lower_limit="36.35" upper_limit="79.29"/>
                    <measurement group_id="O9" value="92.2" lower_limit="81.12" upper_limit="97.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance Time (PCT)</title>
        <description>Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 48 hours. In case a patient received rescue medication before (parasite) clearance, the time to event was censored at the first use of rescue medication.</description>
        <time_frame>Day 29</time_frame>
        <population>Full Analysis Set (FAS). Only participants with parasite at baseline and post-baseline assessment of parasite clearance at the time point are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>KAE609 10 mg SD</title>
            <description>KAE609 10 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O2">
            <title>KAE609 10 mg QD 3 Days</title>
            <description>KAE609 10 mg (QD) for 3 days</description>
          </group>
          <group group_id="O3">
            <title>KAE609 25 mg SD</title>
            <description>KAE609 25 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O4">
            <title>KAE609 25 mg QD 3 Days</title>
            <description>KAE609 25 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O5">
            <title>KAE609 50 mg SD</title>
            <description>KAE609 50 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O6">
            <title>KAE609 50 mg QD 3 Days</title>
            <description>KAE609 50 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O7">
            <title>KAE609 75 mg SD</title>
            <description>KAE609 75 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O8">
            <title>KAE609 150 mg SD</title>
            <description>KAE609 150 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O9">
            <title>Pooled Coartem Control</title>
            <description>control arm</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance Time (PCT)</title>
          <description>Parasite Clearance Time (PCT) is defined as the time from the first dose until the first total and continued disappearance of asexual parasite forms which remained at least a further 48 hours. In case a patient received rescue medication before (parasite) clearance, the time to event was censored at the first use of rescue medication.</description>
          <population>Full Analysis Set (FAS). Only participants with parasite at baseline and post-baseline assessment of parasite clearance at the time point are included in the analysis.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="5.44"/>
                    <measurement group_id="O2" value="27.7" spread="4.96"/>
                    <measurement group_id="O3" value="14.0" spread="2.63"/>
                    <measurement group_id="O4" value="11.4" spread="1.82"/>
                    <measurement group_id="O5" value="11.1" spread="1.58"/>
                    <measurement group_id="O6" value="9.8" spread="0.97"/>
                    <measurement group_id="O7" value="8.7" spread="0.97"/>
                    <measurement group_id="O8" value="8.0" spread="1.09"/>
                    <measurement group_id="O9" value="36.2" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever Clearance Time (FCT)</title>
        <description>Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral/tympanic/rectal for at least a further 24 hours. In case a patient received rescue medication before (fever) clearance, the time to event was censored at the first use of rescue medication.</description>
        <time_frame>Day 29</time_frame>
        <population>Full Analysis Set (FAS). Only participants with fever at baseline and post-baseline assessment of fever clearance at the time point are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>KAE609 10 mg SD</title>
            <description>KAE609 10 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O2">
            <title>KAE609 10 mg QD 3 Days</title>
            <description>KAE609 10 mg (QD) for 3 days</description>
          </group>
          <group group_id="O3">
            <title>KAE609 25 mg SD</title>
            <description>KAE609 25 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O4">
            <title>KAE609 25 mg QD 3 Days</title>
            <description>KAE609 25 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O5">
            <title>KAE609 50 mg SD</title>
            <description>KAE609 50 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O6">
            <title>KAE609 50 mg QD 3 Days</title>
            <description>KAE609 50 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O7">
            <title>KAE609 75 mg SD</title>
            <description>KAE609 75 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O8">
            <title>KAE609 150 mg SD</title>
            <description>KAE609 150 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O9">
            <title>Pooled Coartem Control</title>
            <description>control arm</description>
          </group>
        </group_list>
        <measure>
          <title>Fever Clearance Time (FCT)</title>
          <description>Fever Clearance Time (FCT) is defined as the time from the first dose until the first time the axillary body temperature decreased below and remained below 37.5°C axillary or 38.0°C oral/tympanic/rectal for at least a further 24 hours. In case a patient received rescue medication before (fever) clearance, the time to event was censored at the first use of rescue medication.</description>
          <population>Full Analysis Set (FAS). Only participants with fever at baseline and post-baseline assessment of fever clearance at the time point are included in the analysis.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="NA">NA: Not Estimable due to number of events censored</measurement>
                    <measurement group_id="O2" value="2.0" spread="0.02"/>
                    <measurement group_id="O3" value="NA" spread="NA">NA: Not Estimable due to number of events censored</measurement>
                    <measurement group_id="O4" value="22.0" spread="14.03"/>
                    <measurement group_id="O5" value="2.4" spread="0.93"/>
                    <measurement group_id="O6" value="7.2" spread="1.47"/>
                    <measurement group_id="O7" value="5.7" spread="2.02"/>
                    <measurement group_id="O8" value="9.9" spread="3.88"/>
                    <measurement group_id="O9" value="13.0" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recrudescence and Reinfection at Study Day 29</title>
        <description>Time to recrudescence is calculated from the date of first study medication to the date of first event. Participants without recrudescence/reinfection after Day 7 are censored at the time of treatment failure or at the time of last parasite assessment if no treatment failure occured.</description>
        <time_frame>Day 29</time_frame>
        <population>Full Analysis Set (FAS). Only participants with clearance of initial infection before Day 15 and recrudescence/reinfection are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>KAE609 10 mg SD</title>
            <description>KAE609 10 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O2">
            <title>KAE609 10 mg QD 3 Days</title>
            <description>KAE609 10 mg (QD) for 3 days</description>
          </group>
          <group group_id="O3">
            <title>KAE609 25 mg SD</title>
            <description>KAE609 25 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O4">
            <title>KAE609 25 mg QD 3 Days</title>
            <description>KAE609 25 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O5">
            <title>KAE609 50 mg SD</title>
            <description>KAE609 50 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O6">
            <title>KAE609 50 mg QD 3 Days</title>
            <description>KAE609 50 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O7">
            <title>KAE609 75 mg SD</title>
            <description>KAE609 75 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O8">
            <title>KAE609 150 mg SD</title>
            <description>KAE609 150 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O9">
            <title>Pooled Coartem Control</title>
            <description>control arm</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recrudescence and Reinfection at Study Day 29</title>
          <description>Time to recrudescence is calculated from the date of first study medication to the date of first event. Participants without recrudescence/reinfection after Day 7 are censored at the time of treatment failure or at the time of last parasite assessment if no treatment failure occured.</description>
          <population>Full Analysis Set (FAS). Only participants with clearance of initial infection before Day 15 and recrudescence/reinfection are included in the analysis.</population>
          <units>Event probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recrudescence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="1.86" upper_limit="61.30"/>
                    <measurement group_id="O2" value="10.0" lower_limit="1.47" upper_limit="52.70"/>
                    <measurement group_id="O3" value="16.7" lower_limit="4.45" upper_limit="51.83"/>
                    <measurement group_id="O4" value="10.0" lower_limit="2.60" upper_limit="34.40"/>
                    <measurement group_id="O5" value="16.0" lower_limit="5.42" upper_limit="41.93"/>
                    <measurement group_id="O6" value="26.3" lower_limit="11.90" upper_limit="52.11"/>
                    <measurement group_id="O7" value="15.9" lower_limit="5.40" upper_limit="41.67"/>
                    <measurement group_id="O8" value="32.5" lower_limit="16.93" upper_limit="56.43"/>
                    <measurement group_id="O9" value="2.4" lower_limit="0.34" upper_limit="15.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reinfection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="25.0" lower_limit="6.91" upper_limit="68.52"/>
                    <measurement group_id="O4" value="14.3" lower_limit="3.78" upper_limit="46.06"/>
                    <measurement group_id="O5" value="5.0" lower_limit="0.72" upper_limit="30.53"/>
                    <measurement group_id="O6" value="10.0" lower_limit="1.47" upper_limit="52.70"/>
                    <measurement group_id="O7" value="10.3" lower_limit="2.67" upper_limit="35.25"/>
                    <measurement group_id="O8" value="13.3" lower_limit="3.51" upper_limit="43.61"/>
                    <measurement group_id="O9" value="2.4" lower_limit="0.34" upper_limit="15.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Peak Observed Concentration (Cmax)</title>
        <description>Maximum Peak Observed Concentration (Cmax)</description>
        <time_frame>Day 1, Day 3</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>KAE609 10 mg SD</title>
            <description>KAE609 10 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O2">
            <title>KAE609 10 mg QD 3 Days</title>
            <description>KAE609 10 mg (QD) for 3 days</description>
          </group>
          <group group_id="O3">
            <title>KAE609 25 mg SD</title>
            <description>KAE609 25 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O4">
            <title>KAE609 25 mg QD 3 Days</title>
            <description>KAE609 25 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O5">
            <title>KAE609 50 mg SD</title>
            <description>KAE609 50 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O6">
            <title>KAE609 50 mg QD 3 Days</title>
            <description>KAE609 50 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O7">
            <title>KAE609 75 mg SD</title>
            <description>KAE609 75 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O8">
            <title>KAE609 150 mg SD</title>
            <description>KAE609 150 mg once daily (QD) for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Peak Observed Concentration (Cmax)</title>
          <description>Maximum Peak Observed Concentration (Cmax)</description>
          <population>PK Analysis Set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" spread="38.2"/>
                    <measurement group_id="O2" value="185" spread="51.2"/>
                    <measurement group_id="O3" value="379" spread="42.1"/>
                    <measurement group_id="O4" value="503" spread="44.3"/>
                    <measurement group_id="O5" value="773" spread="32.4"/>
                    <measurement group_id="O6" value="828" spread="35.4"/>
                    <measurement group_id="O7" value="1270" spread="41.3"/>
                    <measurement group_id="O8" value="2360" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="235" spread="37.0"/>
                    <measurement group_id="O4" value="655" spread="27.9"/>
                    <measurement group_id="O6" value="1210" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Tmax</description>
        <time_frame>Day 1, Day 3</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>KAE609 10 mg SD</title>
            <description>KAE609 10 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O2">
            <title>KAE609 10 mg QD 3 Days</title>
            <description>KAE609 10 mg (QD) for 3 days</description>
          </group>
          <group group_id="O3">
            <title>KAE609 25 mg SD</title>
            <description>KAE609 25 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O4">
            <title>KAE609 25 mg QD 3 Days</title>
            <description>KAE609 25 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O5">
            <title>KAE609 50 mg SD</title>
            <description>KAE609 50 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O6">
            <title>KAE609 50 mg QD 3 Days</title>
            <description>KAE609 50 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O7">
            <title>KAE609 75 mg SD</title>
            <description>KAE609 75 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O8">
            <title>KAE609 150 mg SD</title>
            <description>KAE609 150 mg once daily (QD) for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Tmax</description>
          <population>PK Analysis Set</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="1.02" upper_limit="12.10"/>
                    <measurement group_id="O2" value="3.92" lower_limit="1.03" upper_limit="6.17"/>
                    <measurement group_id="O3" value="4.01" lower_limit="2.00" upper_limit="8.33"/>
                    <measurement group_id="O4" value="4.25" lower_limit="2.00" upper_limit="23.80"/>
                    <measurement group_id="O5" value="4.12" lower_limit="1.97" upper_limit="10.00"/>
                    <measurement group_id="O6" value="4.12" lower_limit="2.00" upper_limit="6.13"/>
                    <measurement group_id="O7" value="6.01" lower_limit="3.97" upper_limit="12.30"/>
                    <measurement group_id="O8" value="8.07" lower_limit="1.00" upper_limit="24.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="52.7" lower_limit="50.00" upper_limit="60.60"/>
                    <measurement group_id="O4" value="52.1" lower_limit="49.90" upper_limit="59.60"/>
                    <measurement group_id="O6" value="52.0" lower_limit="50.00" upper_limit="60.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24</title>
        <description>AUC0-24</description>
        <time_frame>Day 1, Day 3</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>KAE609 10 mg SD</title>
            <description>KAE609 10 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O2">
            <title>KAE609 10 mg QD 3 Days</title>
            <description>KAE609 10 mg (QD) for 3 days</description>
          </group>
          <group group_id="O3">
            <title>KAE609 25 mg SD</title>
            <description>KAE609 25 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O4">
            <title>KAE609 25 mg QD 3 Days</title>
            <description>KAE609 25 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O5">
            <title>KAE609 50 mg SD</title>
            <description>KAE609 50 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O6">
            <title>KAE609 50 mg QD 3 Days</title>
            <description>KAE609 50 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O7">
            <title>KAE609 75 mg SD</title>
            <description>KAE609 75 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O8">
            <title>KAE609 150 mg SD</title>
            <description>KAE609 150 mg once daily (QD) for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24</title>
          <description>AUC0-24</description>
          <population>PK Analysis Set</population>
          <units>h*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="48.9"/>
                    <measurement group_id="O2" value="2.59" spread="38.0"/>
                    <measurement group_id="O3" value="5.14" spread="52.5"/>
                    <measurement group_id="O4" value="8.39" spread="45.1"/>
                    <measurement group_id="O5" value="11.6" spread="37.7"/>
                    <measurement group_id="O6" value="15.6" spread="27.2"/>
                    <measurement group_id="O7" value="21.4" spread="41.5"/>
                    <measurement group_id="O8" value="40.4" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3.90" spread="38.5"/>
                    <measurement group_id="O4" value="10.9" spread="29.7"/>
                    <measurement group_id="O6" value="21.6" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life (T^1/2)</title>
        <description>Half-life (T^1/2)</description>
        <time_frame>Upto day 15 post dose</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>KAE609 10 mg SD</title>
            <description>KAE609 10 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O2">
            <title>KAE609 10 mg QD 3 Days</title>
            <description>KAE609 10 mg (QD) for 3 days</description>
          </group>
          <group group_id="O3">
            <title>KAE609 25 mg SD</title>
            <description>KAE609 25 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O4">
            <title>KAE609 25 mg QD 3 Days</title>
            <description>KAE609 25 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O5">
            <title>KAE609 50 mg SD</title>
            <description>KAE609 50 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O6">
            <title>KAE609 50 mg QD 3 Days</title>
            <description>KAE609 50 mg once daily (QD) for 3 days</description>
          </group>
          <group group_id="O7">
            <title>KAE609 75 mg SD</title>
            <description>KAE609 75 mg once daily (QD) for 1 day</description>
          </group>
          <group group_id="O8">
            <title>KAE609 150 mg SD</title>
            <description>KAE609 150 mg once daily (QD) for 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (T^1/2)</title>
          <description>Half-life (T^1/2)</description>
          <population>PK Analysis Set</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="8.70"/>
                    <measurement group_id="O2" value="18.5" spread="6.24"/>
                    <measurement group_id="O3" value="35.1" spread="13.9"/>
                    <measurement group_id="O4" value="17.4" spread="3.27"/>
                    <measurement group_id="O5" value="31.5" spread="17.4"/>
                    <measurement group_id="O6" value="32.8" spread="5.05"/>
                    <measurement group_id="O7" value="25.3" spread="8.94"/>
                    <measurement group_id="O8" value="29.9" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="32.4" spread="14.8"/>
                    <measurement group_id="O4" value="30.1" spread="14.0"/>
                    <measurement group_id="O6" value="29.9" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs reported in this record are treatment emergent AEs, collected from date of First Patient First Treatment until the completion of the safety follow-up ( 30 days after the Last Patient Last Treatment ) up to approximately 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>KAE609 10mg SD</title>
          <description>KAE609 10mg SD</description>
        </group>
        <group group_id="E2">
          <title>KAE609 10mg QD@3 Days</title>
          <description>KAE609 10mg QD@3 days</description>
        </group>
        <group group_id="E3">
          <title>KAE609 25mg SD</title>
          <description>KAE609 25mg SD</description>
        </group>
        <group group_id="E4">
          <title>KAE609 25mg QD@3 Days</title>
          <description>KAE609 25mg QD@3 days</description>
        </group>
        <group group_id="E5">
          <title>KAE609 50mg SD</title>
          <description>KAE609 50mg SD</description>
        </group>
        <group group_id="E6">
          <title>KAE609 50mg QD@3 Days</title>
          <description>KAE609 50mg QD@3 days</description>
        </group>
        <group group_id="E7">
          <title>KAE609 75mg SD</title>
          <description>KAE609 75mg SD</description>
        </group>
        <group group_id="E8">
          <title>KAE609 150mg SD</title>
          <description>KAE609 150mg SD</description>
        </group>
        <group group_id="E9">
          <title>Pooled Coartem</title>
          <description>Pooled Coartem</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="25" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Treatment failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Parasitic gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

